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Objectives: To compare the efﬁcacy and safety of the salmeterol/ﬂuticasone propionate
combination product with concurrent sustained release theophylline plus ﬂuticasone
propionate in adult Japanese patients with persistent asthma.
Design: Multicentre, randomised, double-blind, double-dummy, parallel-group study.
Patients and interventions: Three hundred and eighty-three asthmatic patients receiving
sustained release theophylline 200–400mg/day entered the study and were randomised to
receive either salmeterol/ﬂuticasone propionate combination (SFC) 50 mg/250 mg+1
placebo tablet, ﬂuticasone propionate 250 mg+1 sustained release theophylline 200mg
(SR-T+FP), twice daily for 8 weeks.
Results: The adjusted mean change morning peak expiratory ﬂow (PEF) over 8 weeks was
29.8 L/min in the SFC group and 16.3 L/min in the SR-T+FP group, with a treatment
difference of 13.4 L/min (p ¼ 0.0004). SFC improved evening PEF, FEV1, _V50 and _V25 at the
completion of treatment to a greater extent than SR-T+FP (all po0.05). A higherElsevier Ltd. All rights reserved.
system; PEF, peak expiratory ﬂow; FAS, full analysis set; FEV1, forced expiratory volume in 1 s; FP,
ital capacity; ICS, inhaled corticosteroids; LABA, long-acting b2-agonist; PPS, per protocol set; SR-T,
P, sustained release theophylline plus ﬂuticasone propionate; SFC, salmeterol/ﬂuticasone propionate
ﬂow rate at 50% of vital capacity; _V25, maximal expiratory ﬂow rate at 25% of vital capacity.
ocal institutional review boards for all participating centres and conducted in accordance with the
ical Practice (GCP).
784 8661; fax: +81 3 3788 1990.
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M. Adachi et al.1056percentage of patients on SFC were symptom free (p ¼ 0.0286) and rescue free (ns) than
those on SR-T+FP. There was not a statistically signiﬁcant difference between treatments
in symptom scores. Both treatments were well tolerated.
Conclusions: The ﬁnding that SFC was associated with greater improvements in lung
function than SR-T+FP, a commonly employed treatment for asthmatic patients in Japan,
suggests that SFC should be the preferred therapeutic option in these patients.
& 2008 Elsevier Ltd. All rights reserved.Introduction
A nationwide survey (the Asthma Insights & Reality in Japan
survey) in 2000 assessed the current status of asthma
treatment and management in Japan and demonstrated that
despite the availability of a wide range of treatments, the
burden of asthma was signiﬁcant, with about 70% of adults
and 60% of children reporting some limitation of daily life
activities.1 Furthermore, the survey showed that many
patients tended to underestimate the severity of their
disease, and management fell far short of the goals
recommended by the treatment guidelines.
It is well established that asthma is a chronic lung disease
that is primarily characterised by airway inﬂammation and
smooth muscle dysfunction (including bronchoconstriction
and increased airways responsiveness), and asthma can be
treated effectively with a combination of an inhaled
corticosteroid (ICS) and a bronchodilator.2 Indeed, several
well-controlled trials have demonstrated that addition of
the long-acting b2-agonist (LABA) salmeterol to an existing
ICS regimen improved lung function and/or reduced re-
spiratory symptoms in asthmatic patients not properly
controlled on ICS alone to a signiﬁcantly greater extent
than the ICS alone or increasing the dose of ICS.3–10
Theophylline accounts for more than 65% of patients who
need additional treatment to ICS in Japan. To date, no study
has directly compared the effect of salmeterol and
theophylline as add-on therapies to ICS; a meta-analysis of
studies directly comparing the efﬁcacy and safety of
salmeterol and theophylline has demonstrated that salme-
terol is signiﬁcantly superior to theophylline with respect to
improving morning and evening peak expiratory ﬂow (PEF),
reducing daytime and night-time symptoms, reducing rescue
medication use and reducing adverse events that lead to
withdrawal of patients from the studies.11
The well-documented superiority of the combination of
ICS plus LABA for the treatment of asthma has led to this
form of therapy being recommended by the current
international asthma guidelines (Global Initiative for Asth-
ma)2 as the ﬁrst-choice treatment option for patients with
moderate-to-severe persistent asthma; this option is pre-
ferred to increasing the dose of the ICS or using sustained
release theophylline (SR-T) or a leukotriene modiﬁer as add-
on therapy to ICS.12–14 Despite this recommendation, and
the fact that theophylline requires careful dose titration due
to its relatively narrow therapeutic index, theophylline is
widely used in clinical practice in Japan.
In view of the lack of any direct comparison between
combined salmeterol plus ﬂuticasone propionate (FP),
even in separate inhalers, and concurrent SR-T plus
FP in asthmatic patients, the aim of this study was toevaluate add-on treatment to FP, comparing continuous
treatment of SR-T vs switching from SR-T to salmeterol, i.e.
salmeterol/FP combination (SFC) in Japanese adult asth-
matics who were previously using SR-T and ICS.
Patients and methods
Patients
Adult asthmatic patients giving written informed consent to
participate in the study were screened. All patients had a
documented history of bronchial asthma for at least 6
months and were receiving SR-T 200–400mg/day.
Patients who had experienced any life-threatening
asthma exacerbation in the year before screening were
excluded, as were those who had received injections of
corticosteroids within 4 weeks of screening, oral corticos-
teroids (at a dosage of prednisolone 10mg/day or equiva-
lent) within 2 weeks of screening, or were currently
receiving ICS at a dosage of more than FP 800 mg/day or
equivalent, or inhaled short-acting b2-agonists alone.
Patients with known or suspected hypersensitivity to FP,
salmeterol, theophylline or salbutamol, or with any serious,
uncontrolled, systemic disease, including serious psycholo-
gical disorders, or with viral or bacterial infection within 4
weeks of screening or patients who had ever experienced
serious side effects with xanthines were also excluded.
Pregnant or lactating women and women of childbearing
potential were excluded.
Study design
This was a randomised, double-blind, double-dummy,
parallel-group study performed in adult asthmatic patients
in 56 centres in Japan. Patients fulﬁlling the entry criteria
entered a 2-week run-in period, at the beginning of which
hereinafter demographic data were collected. This time
point is designated as visit 1. All patients continued taking
their asthma medications at the same dosage as before
screening, and eligibility to continue in the study was
conﬁrmed at the end of the run-in period designated as visit
2. Clinical laboratory tests were performed, and vital signs
and pulmonary function (spirometric tests) were assessed in
each patient at visit 1 or 2. All eligible patients had a mean
morning PEF of 50–80% of the predicted value during the last
7 consecutive days of the run-in period and PEF of 40–85% of
predicted measured after administration of salbutamol
200–400 mg at visit 1 or 2, and asthma symptoms for at
least 2 of the last 7 consecutive days of the run-in period,
recorded appropriately in an asthma diary.
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Salmeterol/ﬂuticasone vs ﬂuticasone+theophylline 1057Eligible patients were randomised to twice-daily treatment
with either salmeterol/FP 50mg/250mg via a multi-dose
powder inhaler (Diskuss) plus 1 placebo tablet (SFC group)
or concurrent FP 250mg via Diskuss plus 1 SR-T 200mg tablet
(SR-T+FP group), and instructed to take the study medication
for 8 weeks. FP 50mg/250mg Diskuss and FP 250mg Diskuss
were supplied from GlaxoSmithKline KK, Japan and SR-T
200mg and matching placebo were supplied from Eisai Co.
Ltd, Japan. Patients returned to the clinic at weeks 2, 4 and 8
designated as visits 3, 4 and 5, respectively, at which time
they underwent clinical laboratory tests and were assessed
for vital signs, 12-lead ECG, lung function by spirometry and
compliance with study medication.
The primary endpoint was the mean change from baseline
in morning PEF over the 8-week study period. Secondary
endpoints included mean change in morning and evening PEF
each week for 8 weeks, changes from baseline in spirometry
measures, percentage of patients with medication-free
days, percentage of patients with symptom-free days, and
change from baseline in symptom scores. The mean change
in morning PEF on treatment days 1–7 was assessed as a
post-hoc analysis.
Over the course of the entire study period, patients made
daily diary card recordings of morning PEF, evening PEF,
severity of asthma, amount of sputum in daily activities,
night-time sleep, compliance with study drugs, use of rescue
medication, and adverse events. The severity of asthma
symptoms were recorded in the patients’ asthma diaries.
The symptom score was calculated from the sum of severity
of symptoms (9 ¼ severe attack, 6 ¼ moderate attack,
3 ¼ mild attack, 1 ¼ wheezing, 1 ¼ chest tightness, 0 ¼ no
symptom), severity of cough (1 ¼ strong, 0.5 ¼ weak) and
amount of sputum (1 ¼ a lot, 0.5 ¼ a little), and of night-
time sleep was evaluated by the level of sleep disturbance
(12 ¼ could not sleep at all due to breathlessness, 8 ¼ could
not sleep well due to breathlessness, 4 ¼ could sleep even
though I felt breathlessness, 0 ¼ could sleep very well). At
the end of the treatment period, all patients were followed
up for 2 weeks, during which time they were not restricted
to any asthma medications.
The study was approved by each local institutional review
board for all participating centres and conducted in
accordance with the Declaration of Helsinki, and Good
Clinical Practice (GCP).
PEF measurements were made with a Mini-Wright Peak
Flow Meter. Patients made three measurements each
morning and evening before taking their study medications,
and recorded the best of the three measurements each
time. Spirometry was used to measure forced expiratory
volume in 1 s (FEV1), forced vital capacity (FVC), maximal
expiratory ﬂow rate at 50% of vital capacity ( _V50) and
maximal expiratory ﬂow rate at 25% of vital capacity ( _V25).Statistical analysis
The objective of the primary efﬁcacy analysis was to
demonstrate that SFC was either non-inferior or superior
to SR-T+FP, on the basis of a difference in the change from
baseline in mean morning PEF between the two treatment
groups, using a non-inferiority criterion limit of 15 L/min.
On this basis, and assuming a standard deviation for thedifference between groups of 40 L/min, it was estimated
that 151 patients were required per treatment group (total
of 302 patients) to demonstrate a signiﬁcant difference at
the 5% level (two-sided t-test) with 90% power. Non-
inferiority of SFC would be demonstrated if the lower limit
of the 95% conﬁdence interval (CI) for the difference lay
above 15 L/min. Superiority would be demonstrated if the
lower 95% CI exceeded 0 L/min.
The primary endpoint was evaluated by ANCOVA, with
treatment groups as explanatory variables and gender, age,
pre-study values and study centre as covariates. Mean
weekly change in morning and evening PEF, and mean
change in evening PEF over the 8-week period were also
assessed by ANCOVA. For spirometry variables, the differ-
ence between treatment groups was calculated using two
sample t-tests.
The percentage of patients who did not use rescue
medication and the percentage of patients with no
symptoms (deﬁned as no symptoms, no cough and no
sputum) in 1 week was calculated for each treatment group
and the differences between the treatment groups were
evaluated using Fisher’s exact test.
The severity of asthma symptoms were recorded in the
patients’ asthma diaries; the symptom score was calculated
from the sum of the severity of symptoms, severity of cough
and amount of sputum, and of night-time sleep was
evaluated by the level of sleep disturbance. The mean and
median change from baseline in symptoms scores and in
night-time sleep scores were calculated for each treatment
group and the two-sided conﬁdence interval for the
treatment difference was estimated using the median.
Since a difference between treatment groups was
observed for mean change in morning PEF at treatment
week 1, and increased in both groups, post-hoc analysis was
conducted to assess mean change over treatment days 1–7.
This was assessed on a daily basis. p-values were also
calculated for efﬁcacy endpoints.
The difference in safety between groups was analysed by
calculating the odds ratio (and 95% CI) for greater incidence
of adverse events in the SR-T+FP group than the SFC group,
using a logistic regression model.
Efﬁcacy and safety were analysed for both the full
analysis set (FAS; deﬁned as all patients who were
randomised to treatment, excluding those who had not
received any treatment and had no efﬁcacy data after
randomisation) and the per-protocol set (PPS; deﬁned as the
subset of patients in the FAS who were compliant with the
protocol).Results
Demographic and baseline characteristics
Figure 1 shows the disposition of patients throughout this
study. A total of 581 patients were screened, of whom 383
(aged 19–78 years) were randomised to treatment with
either SFC (n ¼ 194) or SR-T+FP (n ¼ 189). Of these, 21
(10.8%) patients from the SFC group and 22 (11.6%) from the
SR-T+FP group withdrew from the study for various reasons;
adverse events were the most common cause of withdrawal
(9 and 13 patients, respectively).
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581 patients enrolled
383 randomized
9 adverse event
8 withdraw consensus
7 protocol violation
170 not meeting
      inclusion criteria
194 allocated to salmeterol 50µg/
fluticasone propionate 100µg
combination (SFC 50/100) Diskus,
twice a day
189 allocated to sustained release
theophylline(SR-T) tablet 200mg plus
f luticasone propionate(FP) 100µg
Diskus, twice a day
167 Completed
22 Discontinuations
   1 consent withdrawn
   3 protocol violation
   1 lack of efficacy
13 adverse events
   1 lost to follow-up
   3 other
173 Completed
21 Discontinuations
   5 consent withdrawn
   4 protocol violation
   1 lack of efficacy
   9 adverse events
   1 lost to follow-up
   1 other
198 not randomized
6 others
Figure 1 Disposition of patients throughout the study.
M. Adachi et al.1058Demographic and baseline characteristics of patients in
the FAS are outlined in Table 1. Of note, one of the 189
patients randomised to the SR-T+FP group was excluded
from the FAS and safety populations because of a deviation
from GCP. The proportion of patients who were using 200 to
o400mg/day of SR-Twas 37.1% in the SFC group and 39.4%
in the SR-T+FP group, and the proportion of patients who
were using 400mg/day of SR-T was 62.4% and 60.6%,
respectively. In both treatment groups, 96% of the patients
were using ICSs and approximately 80% of them were using
the equivalent of p400 mg/day of FP. In both treatment
groups, more than 97% of the patients achieved a com-
pliance rate of X80% during the treatment period.
The demographic and baseline characteristics of the two
treatment groups in the FAS were generally similar, with no
signiﬁcant differences at baseline in pulmonary function, or
the severity of asthma. However, since the Kruskal-Wallis
test showed bias in the duration of asthma (p ¼ 0.0682), this
factor was included in the primary model and the mean
change in morning PEF was calculated. Both values of the
mean change in morning PEF obtained with and without this
factor were similar so the observed bias was considered to
have no inﬂuence on the efﬁcacy evaluation. As the results
from the FAS are very similar to those from the PPS, only the
results for the FAS are presented.Pulmonary function
PEF
The baseline mean (7S.D.) morning PEF was not signiﬁcantly
different for the two treatment groups (332765.4 L/min forthe SFC group and 327768.8L/min for the SR-T+FP group).
The adjusted mean change from baseline in morning PEF
(7S.E.) was 29.872.80 L/min for the SFC group and
16.372.83 L/min for the SR-T+FP group, giving a point
estimate value for the difference between the groups
of 13.473.78 L/min (95% CI ¼ 6.00–20.86 L/min) (Table 2).
This improvement with SFC was therefore on average
1.8-fold greater than the improvement seen with SR-T+FP.
As the lower 95% conﬁdence limit (CL) for the difference
exceeded 0 L/min, this conﬁrmed that SFC was superior to
SR-T+FP.
Treatment with SFC produced a signiﬁcantly greater
improvement in adjusted mean morning PEF than SR-T+FP
from day 1 (Figure 2), and this difference increased
throughout the 8-week study period (Figure 3). Similarly,
assessment of adjusted mean change from baseline in
evening PEF over the 8-week treatment period conﬁrmed
superiority of SFC over SR-T+FP (lower 95% CI of 2.74 L/min;
Figure 4).Spirometric measures
Mean FEV1, FVC, _V50 and _V25 values were not signiﬁcantly
different between the two treatment groups at baseline.
While SFC produced progressive improvement in all four
measures over the 8-week treatment period, the improve-
ments in the SR-T+FP group were smaller and not sustained,
declining towards baseline levels over the second 4 weeks of
treatment (Figure 5). The mean change from baseline at 8
weeks in the SFC group was greater for all four measures
than in the SR-T+FP group, and although the mean
differences between the changes in the two groups were
ARTICLE IN PRESS
Table 1 Patient demographics and baseline characteristics.
Demographic factors SFC group (n ¼ 194) SR-T+FP group (n ¼ 188)
Sex (male/female (%)) 51.5/48.5 47.3/52.7
Age (mean7S.D. (years)) 53.9714.12 53.5715.34
Morning PEF (mean7S.D. (L/min)) 332765.4 327768.8
Mean % predicted morning PEF (mean7S.D. (%)) 66.179.04 66.178.48
FEV1 (mean7S.D. (L)) 1.9270.630 1.9470.670
Severity of asthma (n (%))
Severe 6 (3.1) 5 (2.7)
Moderate 177 (91.2) 168 (89.4)
Mild 11 (5.7) 15 (8.0)
Duration of asthma (n (%))
o5 years 31 (16.0) 41 (21.8)
o10 years 36 (18.6) 34 (18.1)
X10 years 127 (65.5) 113 (60.1)
Smoking history (n (%))
Non-smoker (never smoked) 89 (45.9) 90 (47.9)
Former smoker 67 (34.5) 58 (30.9)
Smoker 38 (19.6) 40 (21.3)
Mean daily dosage equivalent to SR-T during observation period (n (%))
200mg/day to o400mg/day 72 (37.1) 74 (39.4)
400mg/day 121 (62.4) 114 (60.6)
600mg/day 1 (0.5) 0
Mean daily dosage equivalent to FP during observation period (n (%))
None 7 (3.6) 7 (3.7)
o200 mg/day 41 (21.1) 38 (20.2)
201 mg/day to 400 mg/day 105 (54.1) 115 (61.2)
401 mg/day to 800 mg/day 41 (21.1) 28 (14.9)
SFC, salmeterol/ﬂuticasone propionate combination; SR-T+FP, concurrent sustained release theophylline plus ﬂuticasone propionate;
FP, ﬂuticasone propionate; PEF, peak expiratory ﬂow; FEV1, forced expiratory ﬂow in 1 s. Asthma severity classiﬁed according to
Japanese guideline.
Salmeterol/ﬂuticasone vs ﬂuticasone+theophylline 1059small, they were statistically signiﬁcant for FEV1, _V50 and
_V25 but not for FVC (Table 2).Symptoms and rescue medication
The percentage of patients who did not use rescue
medication in 1 week did not change from baseline
(approximately 53%) to treatment week 3 in the SR-T+FP
group, but it increased from 50.3% at baseline to 61.7% at
treatment week 1, and to 72.8% at week 3 in the SFC
group (p ¼ 0.0001). At week 8, it was 63.7% in the SR-T+FP
group and 70.5% in the SFC group, but the difference
was not statistically signiﬁcant (Figure 6). The percentage
of patients with no symptoms at week 1 was 0% at
baseline in both the SFC and SR-T+FP groups, but increased
gradually following treatment in both groups, with signiﬁ-
cantly more SFC recipients than SR-T+FP recipients having
no symptoms at week 8. Patients had only mild symptoms,
like weak cough or a little sputum, and the symptom
scores were 1.7–1.8 and median night-time sleep scores
were 0.0 at baseline. There were no differences in the
median change in symptom scores and night-timesleep scores at week 8 between the two treatment groups
(Table 2).Safety
Table 3 shows an overview of the adverse event proﬁles for
the two treatment groups. The proportion of patients in
each group who reported adverse events of any severity was
almost identical (SFC, 61.9%; SR-T+FP, 61.7%, odds ratio
1.01, 95% CI ¼ 0.67–1.52). The lack of any serious drug-
related adverse events indicates that both treatments were
well tolerated and comparatively safe. However, a total of
four events in three patients (supraventricular tachycardia
in SFC group, humerus fracture and contusion, and
adenocarcinoma in SR-T group) were considered serious
because they were associated with ‘‘hospitalisation or
prolongation of existing hospitalisation’’, but did not require
discontinuation of the study medications. Common adverse
events in both treatment groups were nasopharyngitis,
headache, hoarseness, pharyngolaryngeal pain and asthma.
Eczema was additionally reported in the SFC group and
nausea, back pain and pharyngitis in the SR-T+FP group.
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Table 2 Overview of efﬁcacy.
SFC
group
SR-T+FP
group
Treatment
difference
Two-sided
95% CI
p-Value
Morning PEF (mean (L/min))
Baseline 332 327
Adjusted mean change from baseline at day 1 +18.9 +6.8 12.1 5.11–19.03 0.0007
Adjusted mean change from baseline in 1st week +20.9 +10.2 10.7 4.33–17.06 0.0010
Adjusted mean change from baseline over 8 weeks +29.8 +16.3 13.4 6.00–20.86 0.0004
Evening PEF (mean (L/min))
Baseline 351 345
Adjusted mean change from baseline over 8 weeks +23.7 +13.5 10.1 2.74–17.56 0.0074
FEV1 (mean (L))
Baseline 1.92 1.94
Change from baseline at endpoint +0.17 +0.05 0.12 0.042–0.187 0.0021y
FVC (mean (L))
Baseline 2.84 2.77
Change from baseline at endpoint +0.14 +0.06 0.08 0.006–0.162 0.0713y
_V50 (mean (L/s))
Baseline 1.69 1.82
Change from baseline at endpoint +0.28 +0.04 0.23 0.096–0.370 0.0010y
_V50 (mean (L/s))
Baseline 0.64 0.73
Change from baseline at endpoint +0.07 0.02 0.09 0.015–0.163 0.0186y
Symptom score (median)
Baseline 1.7 1.8 –
Change from baseline at week 8 0.5 0.3 0.15 0.440–0.040
Night-time sleep (median)
Baseline 0.0 0.0
Change from baseline after 8 weeks 0.0 0.0 0.0 0.000–0.000
Symptom-free over a week (% patients)
Baseline 0.0 0.0
Change from baseline after 8 weeks 18.2 9.5 – – 0.0286z
Rescue medication-free over a week (% patients)
Baseline 50.3 53.2
Change from baseline after 8 weeks 70.5 63.7 – – 0.2069z
SFC, salmeterol/ﬂuticasone propionate combination; SR-T+FP, concurrent sustained release theophylline plus ﬂuticasone propionate;
PEF, peak expiratory ﬂow; FEV1, forced expiratory ﬂow in 1 s; FVC, forced vital capacity; _V50, maximal expiratory ﬂow rate at 50% of
vital capacity; _V25, maximal expiratory ﬂow rate at 25% of vital capacity.
ANCOVA.
yTwo sample t-tests.
zFisher’s exact test.
M. Adachi et al.1060Analysis of the incidence of drug-related adverse events
(SFC, 16.0%; SR-T+FP, 18.6%) by a logistic regression model
demonstrated that the two treatments were not signiﬁ-
cantly different in this respect, as indicated by an odds ratio
of 0.83 (95% CI ¼ 0.49–1.41). As Table 3 shows, the most
common drug-related adverse events observed in the study
were hoarseness and nausea. Withdrawal rate from adverse
events was 1.0% in the SFC group and 3.2% in the SR-T+FP
group; these adverse events were reversible after terminat-
ing treatment. No severe adverse events were reported in
either group. No signiﬁcant changes were observed inclinical laboratory tests, vital signs, or 12-lead ECG in either
treatment group.Discussion
To our knowledge, this is the ﬁrst study to directly compare
the efﬁcacy and safety of SFC with concurrent therapy of
theophylline and FP in asthmatic patients. This study has
clearly demonstrated that SFC 50 mg/250 mg is superior to or
at least as good as SR-T 200mg+FP 250 mg, in lung function
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Figure 2 Adjusted mean change from baseline (7S.E.) in
morning PEF for each day over the ﬁrst 7 days (*po0.01,
ypo0.05 vs SR-T+FP group). SFC, salmeterol/ﬂuticasone pro-
pionate combination; SR-T+FP, sustained release theophylline+
ﬂuticasone propionate.
0
5
10
15
20
25
30
35
40
0
Treatment period (week)
M
ea
n 
ch
an
ge
 fr
om
 b
as
el
in
e 
(L
/m
in)
SFC SR-T+FP
∗
∗
∗
∗
∗
∗
∗
∗
1 2 3 4 5 67 8 1-8
∗
Figure 3 Adjusted mean change from baseline (7S.E.) in
morning PEF for each week of the 8-week treatment period
(*po0.01 vs SR-T+FP group). SFC, salmeterol/ﬂuticasone pro-
pionate combination; SR-T+FP, sustained release theophylline+
ﬂuticasone propionate; 1–8 means average of each weeks from
1 to 8 weeks.
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Figure 4 Adjusted mean change from baseline (7S.E.) in
evening PEF for each week of the 8-week treatment period
(*po0.01, ypo0.05 vs SR-T+FP group). SFC, salmeterol/
ﬂuticasone propionate combination; SR-T+FP, sustained release
theophylline+ﬂuticasone propionate; 1–8 means average of
each weeks from 1 to 8 weeks.
Salmeterol/ﬂuticasone vs ﬂuticasone+theophylline 1061endpoints, symptom scores and safety, when both are given
twice daily for 8 weeks to Japanese patients with persistent
Asthma The improvement in lung function, measured as the
change from baseline in morning PEF (the primary end-
point), was apparent from day 1 in the SFC group, and was
nearly double the improvement produced by SR-T+FP over
the whole 8-week treatment period. It is probable, however,
that the improvements from baseline noted in patients
treated with SR-T+FP were largely due to the FP component
because prior to entry into the study all patients were
receiving theophylline as their normal medication, 96% of
patients had ICS at baseline and approximately 80% of
patients increased the equivalent dose of FP, while 40%
increased the dose of SR-T. Although the percentage of
patients who did not have symptoms, and the percentage of
patients who did not use rescue medication, improved in
both groups, and the improvements with SFC were consis-
tently greater than those with SR-T+FP, the differencebetween the treatment groups reached statistical signiﬁ-
cance at week 8 for the symptom-free endpoint. The
patients had very mild symptoms at baseline, and there
were no differences in symptom scores and night-time sleep
scores at week 8 between the treatment groups. These
parameters were, however, analysed as secondary end-
points; the study was not powered to demonstrate a
statistically signiﬁcant difference between the groups for
these parameters.
Although a meta-analysis from nine clinical studies has
demonstrated that safety of salmeterol is signiﬁcantly
superior to theophylline with respect to reducing adverse
events that lead to withdrawal of patients,11 there was no
statistical difference between the two groups with respect
to drug-related adverse event rates, withdrawal rate from
adverse events and no severe adverse event was reported in
either group. Cardiovascular symptoms, commonly reported
with b2 agonists, was experienced by 1.0% of the SFC group
and 1.6% of the SR-T+FP group and rate of reduction in blood
potassium levels was 1.0% in the SFC group and 0.5% in the
SR-T+FP group. Gastrointestinal symptoms, commonly re-
ported in the early stages of theophylline treatment, were
reported by 3.6% of the SFC group and 3.2% of the SR-T
group. These data are also different from a reported meta-
analysis where gastrointestinal disturbance was signiﬁcantly
lesser in salmeterol recipients. Because patients in this
study had already been treated with theophylline at
baseline and patients who had ever experienced serious
side effects with xanthines were excluded, patients may
have had some tolerability to theophylline thus avoiding
these well-documented adverse events during the theophyl-
line initiating period or dose escalation. Theophylline needs
careful dose titration and regular monitoring of blood levels
at 10–20 mg/L in the early stages of initiating therapy or dose
escalation to avoid potential adverse effects.2,15–19
Although this study was conducted in Japanese patients,
we are not aware of any evidence to suggest that results for
non-Japanese patients would differ. In fact, a double-blind,
crossover study found that the extent of improvement in
lung function was similar in Japanese and Caucasian
asthmatics treated with SFC, or salmeterol and FP from
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M. Adachi et al.1062separate inhalers.20 In one study, the pharmacokinetic
proﬁles of Japanese and Caucasian asthmatics treated with
SFC were comparable.21 Furthermore, the pharmacokinetics
of theophylline in healthy Caucasian volunteers22 were
broadly similar to those previously observed in healthy
Japanese volunteers.23 Apart from the clinical advantages of
salmeterol over theophylline as add-on therapy to ICS, a
major advantage of SFC is that it is administered via a singleinhaler (Diskuss), and is therefore more convenient for
patients and physicians than an inhaler plus a tablet, of
which the latter requires titration. Not only it is easy for
physicians, pharmacists and nurses to instruct patients in
the correct use of the Diskuss, but also patients ﬁnd the
device easy to use.24 Diskuss has the potential to be
advantageous in a primary care setting, where it is likely
that use of a single inhaler will increase patient compliance
ARTICLE IN PRESS
Table 3 Overview of safety results.
Patients (n (%))
SFC group (n ¼ 194) SR-T+FP group (n ¼ 188)
Any AE 120 (61.9) 116 (61.7)
Any drug-related AE 31 (16.0) 35 (18.6)
Any SAE 1 (0.5) 2 (1.1)
Any serious drug-related AE 0 (0) 0 (0)
Any AE leading to withdrawal from the study 9 (4.6) 13 (6.9)
Withdrawn from the study due to drug-related AE 2 (1.0) 6 (3.2)
Type of drug-related AE
Hoarseness 13 (6.7) 6 (3.2)
Nausea 2 (1.0) 4 (2.1)
Asthma 0 (0) 3 (1.6)
Hypoaesthesia oral 2 (1.0) 1 (0.5)
Diarrhoea 2 (1.0) 0 (0)
Blood urea increase 0 (0) 3 (1.6)
Blood potassium decrease 2 (1.0) 1 (0.5)
Oral candidiasis 1 (0.5) 2 (1.1)
Palpitations 1 (0.5) 2 (1.1)
Blood bilirubin increase 1 (0.5) 2 (1.1)
Glucose urine present 0 (0) 2 (1.1)
Tremor 0 (0) 2 (1.1)
AE, adverse event; SAE, serious adverse event; SFC, salmeterol/ﬂuticasone propionate combination; SR-T+FP, concurrent sustained
release theophylline plus ﬂuticasone propionate.
Drug-related AEs reported by more than one patient in either group.
Salmeterol/ﬂuticasone vs ﬂuticasone+theophylline 1063and may lead to lower overall treatment costs. Indeed, a
recent cost-effectiveness analysis of different treatments
used for the management of asthmatic patients not
controlled with ICS alone has demonstrated that SFC was
the most cost-effective treatment option when compared
with FP at the same dose, budesonide at maintenance dose,
FP+montelukast, or montelukast alone.25 Furthermore, SFC
was also associated with improvements in health-related
quality of life.26 Similar cost-effectiveness comparisons
between SFC and treatment regimens including theophylline
have not been reported and should provide important
information for healthcare providers.
Conclusions
The results from this study clearly demonstrate that
treatment with SFC (50/250 mg twice daily in a single
inhaler) is superior to concurrent twice a day treatment
with FP 250 mg plus SR-T 200mg in Japanese patients with
persistent asthma, as indicated by signiﬁcantly superior
improvements in markers of asthma control such as lung
function. Both treatments were well tolerated. The results
of this study suggest that SFC is preferable to SR-T+FP for
the treatment of patients with persistent asthma in Japan.
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